Data News > Shareholders of Humacyte, Inc. Encouraged to Take Action Before January 17, 2025

Shareholders of Humacyte, Inc. Encouraged to Take Action Before January 17, 2025

By KlickAnalytics Data Insights  |   December 31, 2024 08:01PM ET

Key Points

- Humacyte, Inc. investors who suffered losses urged to contact various law firms before January 17, 2025
- Class action lawsuits filed against Humacyte, Inc. for alleged securities law violations
- Investors have the opportunity to lead class action lawsuits against the company
- The lawsuits aim to recover damages for investors who purchased Humacyte securities between May 10, 2024, and October 17, 2024
- Shareholders advised to act promptly to potentially recover losses incurred due to securities fraud

Investors who have experienced losses on their investments in Humacyte, Inc. (NASDAQ:HUMA) have been urged to take action before January 17, 2025. Several law firms, including Levi & Korsinsky, Bronstein, Gewirtz & Grossman LLC, Pomerantz Law Firm, Kirby McInerney LLP, and The Schall Law Firm, have announced class action lawsuits against the company and certain officers.

Levi & Korsinsky, a New York-based law firm, is actively notifying shareholders of Humacyte, Inc. about the opportunity to participate in a class action lawsuit in relation to alleged violations of federal securities laws. Investors who wish to learn more about potential recovery under these laws are encouraged to contact Joseph E. Levi, Esq. before the January 17, 2025 deadline.

Bronstein, Gewirtz & Grossman LLC, another renowned law firm, has announced that investors with substantial losses in Humacyte, Inc. also have the opportunity to lead a class action lawsuit against the company and its officers. Similarly, Pomerantz Law Firm is reminding shareholders about a class action lawsuit filed against Humacyte, Inc. for violations of the Securities Exchange Act of 1934.

Kirby McInerney LLP is urging investors who acquired Humacyte, Inc. securities between May 10, 2024, and October 17, 2024, to inquire about their rights regarding the ongoing class action lawsuit. The law firm is reminding investors that they have until January 17, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The Schall Law Firm, based in Los Angeles, is also actively seeking investors who purchased Humacyte, Inc. securities between May 10, 2024, and October 17, 2024, for potential recovery of losses due to violations of securities laws. Investors are advised to contact the firm before the January 17, 2025 deadline to explore their options for participating in the class action lawsuit.

investors who have suffered losses on their investments in Humacyte, Inc. are being encouraged to take action before January 17, 2025, by contacting the various law firms involved in the class action lawsuits. These legal proceedings aim to recover damages for investors who purchased Humacyte securities during the defined class period, potentially holding the company accountable for alleged securities law violations.

For more information:
  • Up/Down Rally
  • Price Distribution
  • Analyst Recommendations
  • Earning Price Impact Analysis
  • Seasonality


  • Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.